Glaukos has secured Australian regulatory approval for the Preserflo MicroShunt, offering late-stage glaucoma patients a more elegant surgical alternative to conventional filtration procedures. Read more
Nova Eye Medical has published two-year data for its iTrack ab-interno canaloplasty procedure, which it says showed an average reduction in mean intraocular pressure (IOP) of 30%, irrespective of whether it was performed standalone or with cataract surgery. Read more
The managing director of one of Australia’s pre-eminent eye research institutions is a leading scientist behind experiments on mice that have shown promise for developing new gene therapies for both glaucoma and dementia. Read more
Advances in glaucoma stent technology far outstripped the Medicare schedule early on, creating a disconnect that had far-reaching consequences. As Australia marks World Glaucoma Week this 7-13 March, Insight traces the turbulent MBGS journey that’s now considered an ophthalmology success story.
Nova Eye Medical has announced eight surgery centres across the US have commenced a prospective, randomised clinical trial to assess the efficacy and safety outcomes of ab-interno canaloplasty. Read more
Australian researchers have been at the fore of the largest genetic study of glaucoma that has identified 44 new genetic variants that may lead to new treatment targets. Read more
Nova Eye Medical has announced an application to secure public funding for its iTrack ab-interno canaloplasty as a standalone minimally invasive glaucoma surgery (MIGS) procedure in Australia has formally progressing to the third and final stage of the assessment process. Read more
Glaukos has unveiled a new single-use surgical gonioscopy lens that is said to provide exceptional clarity with expanded views of angle structures. Read more
Medicinal cannabis is often presented as an alternative treatment for glaucoma. Although there is evidence that cannabis lowers intraocular pressure, its role as a viable glaucoma therapy is limited by a short duration of action, psychotropic effects, and possible tachyphylaxis.
A Victorian biopharmaceutical company has reported positive results from a Phase 1 study examining the safety of its biodegradable implant for glaucoma. Read more